Figures & data
Figure 1. A sketch of the preparation of BN-PEG-NLC. BN: baicalin; PEG: polyethylene glycol; NLC: nanostructured lipid carriers.
![Figure 1. A sketch of the preparation of BN-PEG-NLC. BN: baicalin; PEG: polyethylene glycol; NLC: nanostructured lipid carriers.](/cms/asset/679f7362-c451-4535-a9d0-7cfce106e7c3/idrd_a_1223218_f0001_c.jpg)
Table 1. Characterization of NLC.
Figure 2. In vitro release profiles of BN from BN-PEG-NLC, BN-NLC, or BN solution. BN: baicalin; PEG: polyethylene glycol; NLC: nanostructured lipid carriers.
![Figure 2. In vitro release profiles of BN from BN-PEG-NLC, BN-NLC, or BN solution. BN: baicalin; PEG: polyethylene glycol; NLC: nanostructured lipid carriers.](/cms/asset/889155ba-d1d1-4c76-aa92-9f5521dcc546/idrd_a_1223218_f0002_c.jpg)
Figure 3. The plasma concentration-time profiles of BN following single dose i.v. administration of BN solution, BN-NLC, and BN-PEG-NLC. BN: baicalin; PEG: polyethylene glycol; NLC: nanostructured lipid carriers.
![Figure 3. The plasma concentration-time profiles of BN following single dose i.v. administration of BN solution, BN-NLC, and BN-PEG-NLC. BN: baicalin; PEG: polyethylene glycol; NLC: nanostructured lipid carriers.](/cms/asset/9f048ac5-e328-49d1-b8aa-e7c56f825f3d/idrd_a_1223218_f0003_c.jpg)
Table 2. Pharmacokinetic parameters of BN after i.v. injecting of BN solution, BN-NLC, and BN-PEG-NLC in rats at a dose of 10 mg/kg (n = 6).
Figure 4. BN tissue concentration of heart, liver, spleen, lung, kidney, and brain at 15 min following i.v. administration of BN solution, BN-NLC, and BN-PEG-NLC in acute MI rat models. BN: baicalin; PEG: polyethylene glycol; NLC: nanostructured lipid carriers.
![Figure 4. BN tissue concentration of heart, liver, spleen, lung, kidney, and brain at 15 min following i.v. administration of BN solution, BN-NLC, and BN-PEG-NLC in acute MI rat models. BN: baicalin; PEG: polyethylene glycol; NLC: nanostructured lipid carriers.](/cms/asset/6f09ac0c-4560-43fe-8b99-7ffa079f9ab7/idrd_a_1223218_f0004_c.jpg)